| Ligand |
Purity |
Ref. No. |
Pack Size |
| ACEA |
>98% |
Asc-096 |
5mg |
| Potent, selective CB1 agonist |
25mg |
| |
100mg |
| AF-DX 116 |
>99% |
Asc-152 |
10mg |
| M2 antagonist |
50mg |
| AM 251 |
>99% |
Asc-088 |
10mg |
| CB1 receptor antagonist / inverse agonist |
50mg |
| AM404 |
>99% |
Asc-095 |
10mg |
| Anandamide transport inhibitor |
50mg |
| Aminoguanidine hydrochloride |
>98% |
Asc-123 |
100mg |
| NOS inhibitor |
| 4-Aminopyridine |
>99% |
Asc-122 |
100mg |
| K+ channel blocker |
| AMN082 dihydrochloride |
>99% |
Asc-011 |
10mg |
| mGlu7 agonist |
50mg |
| (RS)-AMPA |
>99% |
Asc-130 |
10mg |
| AMPA agonist |
50mg |
| (S)-AMPA |
>98% |
Asc-005 |
5mg |
| AMPA agonist |
10mg |
| |
50mg |
| Anandamide |
>98% |
Asc-087 |
5mg |
| Endogenous cannabinoid |
25mg |
| (±)-Anatoxin A fumarate |
>98% |
Asc-013 |
1mg |
| Potent nicotinic agonist |
| DL-AP4 |
>99% |
Asc-001 |
100mg |
| NMDA receptor antagonist |
1g |
| L-AP4 |
>99% |
Asc-002 |
10mg |
| Selective group III mGlu agonist |
50mg |
| D-AP5 |
>99% |
Asc-003 |
10mg |
| NMDA glutamate site antagonist |
50mg |
| |
100mg |
| DL-AP5 |
>99% |
Asc-004 |
10mg |
| NMDA glutamate site antagonist |
50mg |
| 2-APB |
>98% |
Asc-124 |
100mg |
| Ca2+ release modulator |
| Apigenin |
>98% |
Asc-141 |
10mg |
| Anticancer agent |
50mg |
| AQ-RA 741 |
>99% |
Asc-151 |
10mg |
| M2 antagonist |
50mg |
| (RS)-Baclofen |
>99% |
Asc-149 |
1g |
| GABAB agonist |
| (+)-Bicuculline |
>98% |
Asc-107 |
50mg |
| GABAA antagonist. |
| (-)-Bicuculline methiodide |
>98% |
Asc-108 |
10mg |
| GABAA antagonist. |
50mg |
| (-)-Bicuculline methobromide |
>98% |
Asc-109 |
10mg |
| GABAA antagonist. |
50mg |
| (-)-Bicuculline methochloride |
>98% |
Asc-110 |
10mg |
| GABAA antagonist. |
50mg |
| Nor-Binaltorphimine |
>98% |
Asc-078 |
10mg |
| Potent and selective k opioid receptor antagonist |
50mg |
| Camptothecin |
>98% |
Asc-115 |
50mg |
| DNA topoisomerase inhibitor |
250mg |
| Capsazepine |
>99% |
Asc-025 |
10mg |
| VR1 antagonist |
50mg |
| CGP 37157 |
>99% |
Asc-012 |
10mg |
| Na+-Ca2+ exchange inhibitor |
50mg |
| CGP 37849 |
>99% |
Asc-127 |
10mg |
| Competitive NMDA antagonist |
50mg |
| CGP 39551 |
>99% |
Asc-128 |
10mg |
| Competitive NMDA antagonist |
50mg |
| 2-Chloroadenosine |
>98% |
Asc-037 |
10mg |
| Adenosine agonist |
50mg |
| |
250mg |
| 7-Chlorokynurenic acid |
>99% |
Asc-024 |
10mg |
| NMDA receptor glycine site antagonist |
50mg |
| (S)-5-Chlorowillardiine |
>98% |
Asc-062 |
10mg |
| AMPA / Kainate agonist |
50mg |
| (RS)-CHPG |
>98% |
Asc-039 |
10mg |
| Selective mGlu5 agonist |
50mg |
| Citalopram |
>98% |
Asc-133 |
25mg |
| 5HT reuptake inhibitor |
100mg |
| Clozapine |
>98.5% |
Asc-019 |
50mg |
| Atypical antipsychotic |
500mg |
| CNQX |
>99% |
Asc-017 |
10mg |
| AMPA / kainate antagonist |
25mg |
| |
50mg |
| CNQX disodium salt |
>99% |
Asc-044 |
10mg |
| AMPA / kainate antagonist (water soluble) |
50mg |
| CPCCOEt |
>98% |
Asc-060 |
10mg |
| Selective, non-competitive mGlu1 antagonist |
50mg |
| Cycloheximide |
>98% |
Asc-093 |
100mg |
| Protein synthesis inhibitor |
1g |
| D-Cycloserine |
>99% |
Asc-121 |
50mg |
| NMDA glycine site agonist |
250mg |
| Cyclosporin A |
>99% |
Asc-114 |
25mg |
| PP2B inhibitor |
100mg |
| |
500mg |
| Cyclothiazide |
>98% |
Asc-061 |
10mg |
| AMPA receptor desensitisation inhibitor |
50mg |
| 4-DAMP |
>98% |
Asc-144 |
25mg |
| Muscarinic receptor antagonist |
100mg |
| (S)-3,4-DCPG |
>99% |
Asc-006 |
10mg |
| mGlu8a agonist |
50mg |
| N-Desmethyl clozapine |
>99% |
Asc-026 |
10mg |
| Clozapine metabolite. M1 agonist. |
50mg |
| Desmethyl YM298198 hydrochloride |
>99% |
Asc-016 |
10mg |
| Analogue of mGlu1 antagonist YM298198 |
50mg |
| (R,S)-3,5-DHPG |
>98% |
Asc-020 |
10mg |
| Group I mGlu receptor agonist |
50mg |
| (S)-3,5-DHPG |
>99% |
Asc-007 |
5mg |
| Selective group I mGlu agonist. |
10mg |
| 5,7-Dichlorokynurenic acid |
>99% |
Asc-023 |
10mg |
| NMDA receptor glycine site antagonist |
50mg |
| |
100mg |
| Dihydrokainic acid |
>99% |
Asc-066 |
10mg |
| EAAT2 inhibitor |
50mg |
| DNQX |
>99% |
Asc-018 |
10mg |
| AMPA / kainate antagonist |
50mg |
| E-4031 dihydrochloride |
>99% |
Asc-158 |
10mg |
| HERG K+ channel blocker |
50mg |
| FCCP |
>99% |
Asc-081 |
10mg |
| Mitochondrial oxidative phosphorylation inhibitor |
50mg |
| Fenobam |
>99% |
Asc-034 |
10mg |
| Selective, potent, orally active mGlu5 antagonist |
50mg |
| (S)-5-Fluorowillardiine |
>99% |
Asc-036 |
10mg |
| Potent, selective AMPA agonist |
50mg |
| Fluoxetine hydrochloride |
>99% |
Asc-077 |
10mg |
| 5HT reuptake inhibitor |
50mg |
| Forskolin |
>98% |
Asc-058 |
10mg |
| Adenylate cyclase activator |
50mg |
| |
100mg |
| Genistein |
>99% |
Asc-112 |
10mg |
| Protein tyrosine kinase inhibitor. Anticancer agent. |
50mg |
| |
100mg |
| L-Glutamate |
>99% |
Asc-049 |
1g |
| Excitatory neurotransmitter |
2.5g |
| Glycine |
>99% |
Asc-050 |
100mg |
| Inhibitory neurotransmitter |
1g |
| Granisetron |
>99% |
Asc-125 |
50mg |
| 5HT3 antagonist |
250mg |
| Haloperidol |
>99% |
Asc-080 |
100mg |
| D2 antagonist |
| Herkinorin |
>98% |
Asc-147 |
1mg |
| Non-internalising μ opioid agonist |
| Ibotenic acid |
>98% |
Asc-041 |
5mg |
| Excitotoxic agonist |
25mg |
| ICI 182,780 |
>99% |
Asc-131 |
10mg |
| Estrogen receptor antagonist |
50mg |
| Ifenprodil |
>99% |
Asc-111 |
10mg |
| NR2B-preferring NMDA antagonist |
50mg |
| Ionomycin Ca2+ Salt |
>99% |
Asc-116 |
1mg |
| Ca2+ ionophore. |
5mg |
| Isradipine |
>98% |
Asc-142 |
10mg |
| L-type Ca2+ channel blocker |
50mg |
| Kainic acid |
>99% |
Asc-100 |
10mg |
| Prototypic kainate receptor agonist |
50mg |
| Ketanserin tartrate |
>98% |
Asc-132 |
50mg |
| Selective 5HT2 antagonist. |
250mg |
| Kynurenic acid |
>98% |
Asc-064 |
1g |
| Endogenous ionotropic / nicotinic antagonist |
| (R,S)-MCPG |
>99% |
Asc-033 |
10mg |
| Group I /II metabotropic glutamate antagonist |
50mg |
| (S)-MCPG |
>98% |
Asc-059 |
10mg |
| Group I / II mGlu antagonist |
50mg |
| (R)-(-)-α-Methylhistamine dihydrobromide |
>98% |
Asc-053 |
10mg |
| Potent, selective H3 agonist |
50mg |
| N-Methyllidocaine iodide |
>99% |
Asc-119 |
10mg |
| Anti-arrthymic |
50mg |
| Methyllycaconitine citrate |
>98% |
Asc-072 |
5mg |
| α7- nicotinic receptor antagonist |
25mg |
| Mirtazepine |
>99% |
Asc-068 |
10mg |
| Antidepressant. α2, 5HT2, 5HT3 antagonist. |
50mg |
| (-)-MK 801 maleate |
>99% |
Asc-028 |
10mg |
| Non competitive NMDA antagonist; less active enantiomer |
50mg |
| (+)-MK 801 maleate |
>99% |
Asc-027 |
10mg |
| Non-competitive NMDA antagonist |
50mg |
| MPEP hydrochloride |
>99% |
Asc-008 |
10mg |
| Potent, selective mGlu5 antagonist |
50mg |
| MTEP hydrochloride |
>99% |
Asc-035 |
10mg |
| Potent, selective mGlu5 antagonist |
50mg |
| Muscimol |
>99% |
Asc-094 |
5mg |
| Potent, selective GABAA agonist. |
10mg |
| |
50mg |
| NADA |
>98% |
Asc-099 |
5mg |
| Endogenous CB1 / TRPV1 agonist |
25mg |
| Naloxone hydrochloride |
>98% |
Asc-074 |
100mg |
| Opioid antagonist |
250mg |
| Naltrexone hydrochloride |
>98% |
Asc-075 |
100mg |
| Opioid antagonist |
250mg |
| NBQX |
>99% |
Asc-045 |
10mg |
| AMPA / kainate antagonist |
50mg |
| NBQX disodium salt |
>99% |
Asc-046 |
10mg |
| AMPA / kainate antagonist; water soluble |
50mg |
| Nicotinic acid |
>98% |
Asc-145 |
10g |
| Antidyslipidemic agent |
| Nifedipine |
>99% |
Asc-135 |
250mg |
| L-type Ca2+ channel blocker |
1g |
| Nimodipine |
>98% |
Asc-138 |
100mg |
| L-type Ca2+ channel blocker |
500mg |
| Nitrendipine |
>98% |
Asc-139 |
100mg |
| L-type Ca2+ channel blocker |
500mg |
| (S)-5-Nitrowillardiine |
>98% |
Asc-063 |
10mg |
| AMPA / Kainate agonist |
50mg |
| NMDA |
>98% |
Asc-052 |
50mg |
| Excitotoxic amino acid |
100mg |
| |
500mg |
| Nociceptin |
>95% |
Asc-070 |
1mg |
| ORL1 agonist |
5 |
| Obestatin |
>95% |
Asc-071 |
1mg |
| Endgoenous peptide involved in feeding |
| ODQ |
>99% |
Asc-022 |
10mg |
| Selective, potent inhibitor of NO-sensitive guanylyl cyclase |
50mg |
| Ondansetron |
>98% |
Asc-134 |
10mg |
| Selective 5HT3 antagonist. |
50mg |
| Paclitaxel |
>98% |
Asc-143 |
10mg |
| Anticancer agent |
50mg |
| Paroxetine hydrochloride |
>99% |
Asc-069 |
10mg |
| 5HT uptake inhibitor |
50mg |
| 2,3 cis-Piperidine dicarboxylic acid |
>98% |
Asc-038 |
50mg |
| ionotropic receptor antagonist |
250mg |
| PHCCC |
>98% |
Asc-043 |
10mg |
| Selective allosteric potentiator at mGlu4 |
50mg |
| Phospho-Glycogen Synthase Peptide-2 |
>99% |
Asc-079 |
0.5mg |
| 1mg |
| Pirenzepine dihydrochloride |
>99% |
Asc-153 |
100mg |
| M1 antagonist |
500mg |
| PPADS |
|
Asc-009 |
10mg |
| P2 purinergic receptor antagonist. |
50mg |
| |
250mg |
| cis-PPDA |
>98% |
Asc-047 |
10mg |
| NR2C/NR2D NMDA antagonist |
50mg |
| PPT |
>99% |
Asc-161 |
10mg |
| Subtype selective ERα agonist |
50mg |
| Quisqualic acid |
>99% |
Asc-010 |
5mg |
| Group I mGlu agonist. AMPA agonist |
10mg |
| |
50mg |
| QX-222 |
>99% |
Asc-126 |
10mg |
| Na+ channel blocker |
50mg |
| QX-314 bromide |
>99% |
Asc-117 |
50mg |
| Na+ channel blocker |
100mg |
| QX-314 chloride |
>99% |
Asc-118 |
50mg |
| Na+ channel blocker |
| Reboxetine mesylate |
>99% |
Asc-157 |
10mg |
| Noradrenaline reuptake inhibitor |
50mg |
| (R,S)-Rolipram |
>99% |
Asc-029 |
10mg |
| Selective PDE4 inhibitor |
50mg |
| (R)-(-)-Rolipram |
>98.5% |
Asc-031 |
10mg |
| Selective PDE4 inhibitor |
50mg |
| (S)-(+)-Rolipram |
>99% |
Asc-030 |
10mg |
| PDE4 inhibitor; less active enantiomer |
50mg |
| Ryanodine |
>98% |
Asc-083 |
1mg |
| Ca2+ release modulator |
| Salvinorin A |
>99% |
Asc-084 |
1mg |
| Potent κ agonist |
| D-Serine |
>99% |
Asc-048 |
1g |
| Endogenous NMDA receptor co-agonist |
5g |
| SL 327 |
>99% |
Asc-082 |
10mg |
| MEK inhibitor |
25mg |
| SNAP |
|
Asc-014 |
10mg |
| NO donor |
50mg |
| SP600125 |
>98% |
Asc-065 |
10mg |
| JNK inhibitor |
50mg |
| Spermidine hydrochloride |
>99% |
Asc-057 |
100mg |
| Endogenous polyamine. nNOS inhibitor. |
| Spermine |
>99% |
Asc-051 |
100mg |
| Endogenous polyamine |
1g |
| SR95531 |
>98% |
Asc-042 |
10mg |
| GABAA antagonist |
50mg |
| Staurosporine |
>98% |
Asc-056 |
0.1mg |
| Protein kinase inhibitor |
0.5mg |
| Tetrodotoxin |
>98% |
Asc-054 |
1mg |
| Na+ channel blocker |
| Tetrodotoxin citrate |
>98% |
Asc-055 |
1mg |
| Na+ channel blocker; water-soluble |
| (+/-)-Thalidomide |
>99% |
Asc-032 |
100mg |
| Immunomodulator and anticancer agent |
| Thioperamide maleate |
>99% |
Asc-021 |
10mg |
| Potent, selective H3 antagonist |
50mg |
| Tropisetron hydrochloride |
>99% |
Asc-156 |
10mg |
| 5-HT3 antagonist |
50mg |
| (+)-Tubocurarine |
>99% |
Asc-073 |
10mg |
| ACh receptor antagonist |
50mg |
| Verapamil hydrochloride |
>99% |
Asc-140 |
1g |
| L-type Ca2+ channel blocker |
| (S)-Willardiine |
>98% |
Asc-040 |
10mg |
| AMPA / kainate receptor agonist |
50mg |
| Wortmannin |
>98% |
Asc-148 |
1mg |
| PI3-kinase inhibitor |
5mg |
| XE-991 dihydrochloride |
>99% |
Asc-089 |
10mg |
| Potent, selective KCNQ channel blocker; blocks M current |
50mg |
| Y-27632 dihydrochloride |
>99% |
Asc-129 |
1mg |
| Selective Rho kinase inhibitor |
10mg |
| |
50mg |
| YM298198 hydrochloride |
>99% |
Asc-015 |
10mg |
| Potent, selective mGlu1 antagonist |
50mg |
| ZD7288 |
>98% |
Asc-102 |
10mg |
| Sino-atrial node function modulator |
50mg |
| Zopiclone |
>98% |
Asc-076 |
10mg |
| Benzodiazepine agonist |
50mg |
